Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA drug recalls in 2024

Every FDA drug recall initiated in 2024, newest first, with its risk class, status and the reason the FDA recorded. Use the cause and risk filters to narrow the year down.

557 recalls, newest first.

Class I · High risk

Atovaquone Oral Suspension

Microbial Contamination of a Non-sterile Product: The product was found to be contaminated with Cohnella bacteria.

Terminated Microbial contamination Bionpharma Inc. NDC 69452-252-87 D-0012-2025
Class II · Moderate risk

Refresh P.M.

Lack of Assurance of Sterility: The impacted lots may contain a breach in the tube seal.

Ongoing Sterility / contamination AbbVie Inc. D-0664-2024
Class II · Moderate risk

Hylenex recombinant

cGMP Deviations: Temperature excursion

Terminated Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 18657-117-04 D-0116-2025
Class II · Moderate risk

First Aid Antiseptic Ointment

Incorrect/Undeclared Excipients: The inactive ingredients labeled on the product boxes and tubes are listed as "mineral oil , petrolatum ". The inactive ingredients in the actual product are polyethylene glycol 400 , polyethylene glycol 4000.

Ongoing Chemical / undeclared Zhejiang Jingwei Pharmaceutical Co., Ltd. D-0013-2025
Class II · Moderate risk

Cefixime for Oral Suspension USP

Subpotent Drug- An out of specification ( OOS ) result observed in assay test during 18-month long term stability study.

Terminated Wrong potency / content Lupin Pharmaceuticals Inc. NDC 68180-405-01 D-0648-2024

Recalls by year